IS7947A - Aðferð til að framleiða kristölluð form ljósfræðilegra handhverfa módafíníls - Google Patents
Aðferð til að framleiða kristölluð form ljósfræðilegra handhverfa módafínílsInfo
- Publication number
- IS7947A IS7947A IS7947A IS7947A IS7947A IS 7947 A IS7947 A IS 7947A IS 7947 A IS7947 A IS 7947A IS 7947 A IS7947 A IS 7947A IS 7947 A IS7947 A IS 7947A
- Authority
- IS
- Iceland
- Prior art keywords
- enantiomer
- ray diffraction
- diffraction pattern
- interplanar spacings
- maxima corresponding
- Prior art date
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229960001165 modafinil Drugs 0.000 title abstract 2
- 230000003287 optical effect Effects 0.000 title 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 9
- 239000012453 solvate Substances 0.000 abstract 6
- 238000002441 X-ray diffraction Methods 0.000 abstract 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 230000001777 nootropic effect Effects 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- QARQPIWTMBRJFX-UHFFFAOYSA-N modafinil acid Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)O)C1=CC=CC=C1 QARQPIWTMBRJFX-UHFFFAOYSA-N 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/06—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0216412A FR2849029B1 (fr) | 2002-12-20 | 2002-12-20 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| PCT/FR2003/003799 WO2004060858A1 (fr) | 2002-12-20 | 2003-12-18 | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7947A true IS7947A (is) | 2005-07-19 |
Family
ID=32406320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7947A IS7947A (is) | 2002-12-20 | 2005-07-19 | Aðferð til að framleiða kristölluð form ljósfræðilegra handhverfa módafíníls |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US7132570B2 (is) |
| EP (6) | EP1572635B1 (is) |
| JP (2) | JP4719471B2 (is) |
| KR (1) | KR101050565B1 (is) |
| CN (5) | CN101012189B (is) |
| AR (1) | AR042546A1 (is) |
| AU (2) | AU2003299349C1 (is) |
| BR (1) | BRPI0316916B1 (is) |
| CA (2) | CA2510096C (is) |
| CL (2) | CL2007002450A1 (is) |
| CY (1) | CY1114291T1 (is) |
| DK (1) | DK2343275T3 (is) |
| EA (1) | EA009592B1 (is) |
| EG (1) | EG24849A (is) |
| ES (3) | ES2627808T3 (is) |
| FR (1) | FR2849029B1 (is) |
| HK (1) | HK1225371A1 (is) |
| IL (1) | IL169205A (is) |
| IS (1) | IS7947A (is) |
| MX (1) | MXPA05006525A (is) |
| MY (1) | MY142926A (is) |
| NO (1) | NO335724B1 (is) |
| NZ (2) | NZ571235A (is) |
| PL (1) | PL377196A1 (is) |
| PT (1) | PT2343275E (is) |
| SI (1) | SI2343275T1 (is) |
| TW (1) | TWI344952B (is) |
| UA (1) | UA100964C2 (is) |
| WO (1) | WO2004060858A1 (is) |
| ZA (1) | ZA200504805B (is) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| CN100360117C (zh) | 2002-06-21 | 2008-01-09 | 转化医药公司 | 具有提高的溶出度的药物组合物 |
| FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| AU2003217437A1 (en) * | 2003-03-17 | 2004-10-11 | Hetero Drugs Limited | Novel crystalline forms of lamotrigine |
| CA2519117C (en) * | 2003-03-17 | 2010-03-02 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| JP4842819B2 (ja) * | 2003-09-04 | 2011-12-21 | セフアロン・インコーポレーテツド | モダフィニル組成物 |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| EP1516869A1 (en) | 2003-09-19 | 2005-03-23 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| EP2292213A1 (en) * | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
| EP1718607A4 (en) * | 2004-02-06 | 2008-05-28 | Cephalon Inc | COMPOSITIONS BASED ON MODAFINIL |
| US20090018202A1 (en) | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| US20060086667A1 (en) * | 2004-09-13 | 2006-04-27 | Cephalon, Inc., U.S. Corporation | Methods for the separation of enantiomeric sulfinylacetamides |
| EP1702915A1 (en) * | 2005-03-14 | 2006-09-20 | Cephalon France | Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation |
| WO2007013962A2 (en) * | 2005-07-21 | 2007-02-01 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| JP2009508880A (ja) * | 2006-02-21 | 2009-03-05 | テバ ファーマシューティカル インダストリーズ リミティド | アルモダフィニルの新規な結晶形とその調製方法 |
| EP1954652A2 (en) | 2006-03-01 | 2008-08-13 | Teva Pharmaceutical Industries Ltd | An improved process for the preparation of armodafinil |
| WO2008008879A2 (en) * | 2006-07-12 | 2008-01-17 | Elan Corporation, Plc | Nanoparticulate formulations of modafinil |
| CA2660565C (en) * | 2006-08-14 | 2012-10-09 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
| WO2008070143A1 (en) * | 2006-12-06 | 2008-06-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing armodafinil intermediate |
| WO2008077127A2 (en) * | 2006-12-19 | 2008-06-26 | Lavin Thomas N | Use of modafinil to treat restless leg syndrome |
| US20100234468A1 (en) * | 2007-06-04 | 2010-09-16 | Abhay Gaitonde | Novel process |
| WO2009024863A2 (en) * | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
| US7960586B2 (en) | 2007-08-16 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Purification of armodafinil |
| US20090082462A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched armodafinil |
| US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
| WO2009090663A1 (en) * | 2008-01-15 | 2009-07-23 | Lupin Limited | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof |
| US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
| US20100036164A1 (en) * | 2008-08-06 | 2010-02-11 | Srinivas Areveli | Preparation of armodafinil form i |
| EP2292306B1 (en) * | 2009-09-02 | 2013-05-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device |
| US20130085304A1 (en) * | 2009-11-19 | 2013-04-04 | Ranbaxy Laboratories Limited | Processes for preparation of polymorphic forms of lacosamide |
| CA2786026A1 (en) * | 2010-01-07 | 2011-07-14 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| DK2649187T3 (da) | 2010-12-08 | 2018-01-29 | Codexis Inc | Biokatalysatorer og fremgangsmåder til syntesen af armodafinil |
| JP6116847B2 (ja) * | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | シクロデキストリンとの混合体を含有する錠剤 |
| US10466776B2 (en) * | 2014-06-24 | 2019-11-05 | Paypal, Inc. | Surfacing related content based on user interaction with currently presented content |
| US9967445B2 (en) * | 2014-07-23 | 2018-05-08 | Orcam Technologies Ltd. | Wearable apparatus securable to clothing |
| AU2015354040B2 (en) * | 2014-11-27 | 2019-01-31 | Gc Corporation | Surface treatment agent for wax pattern and method of manufacturing dental prosthesis |
| WO2017064723A1 (en) * | 2015-10-12 | 2017-04-20 | Natco Pharma Ltd | An improved process for the preparation of armodafinil |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1905990A (en) | 1931-01-02 | 1933-04-25 | Hoffmann La Roche | Disubstituted carbamic acid esters of phenols containing a basic constituent |
| GB1197809A (en) | 1968-02-13 | 1970-07-08 | Inst Noguchi | Method for Continuous Optical Resolution of Organic Racemates. |
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2597864B1 (fr) | 1986-04-28 | 1990-11-16 | Lafon Labor | Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique |
| FR2626881B1 (fr) | 1988-02-10 | 1990-07-27 | Lafon Labor | 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2671349B1 (fr) | 1991-01-09 | 1993-04-23 | Lafon Labor | Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant. |
| FR2710337B1 (fr) * | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
| US6894171B1 (en) | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
| CN1249932A (zh) | 1999-09-29 | 2000-04-12 | 付俊昌 | 一种莫达芬尼及其光学对映体l及d异构体的新用途 |
| KR20020071931A (ko) | 2000-01-07 | 2002-09-13 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석 |
| US20010036640A1 (en) | 2000-04-25 | 2001-11-01 | D'amico Kevin L. | System and methods for the high throughput screening of polymorphs |
| US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| US6670358B2 (en) | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
| DE10025756C2 (de) * | 2000-05-25 | 2003-02-20 | Cognis Deutschland Gmbh | Lösungsvermittler |
| KR20060024028A (ko) * | 2000-07-27 | 2006-03-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정질의 순수한 모다피닐 및 이의 제조 방법 |
| US6835307B2 (en) * | 2000-08-04 | 2004-12-28 | Battelle Memorial Institute | Thermal water treatment |
| US6489363B2 (en) | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| US6919378B2 (en) | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| JP2004513956A (ja) | 2000-11-03 | 2004-05-13 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウムｖｉｉ型 |
| KR100911779B1 (ko) | 2001-05-25 | 2009-08-12 | 세파론, 인코포레이티드 | 모다피닐을 포함하는 고형 제약 제제 |
| JP2005502861A (ja) | 2001-08-10 | 2005-01-27 | サイミックス テクノロジーズ， インコーポレイテッド | 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム |
| AU2003205621A1 (en) | 2002-01-15 | 2003-07-30 | Avantium International B.V. | Method for performing powder diffraction analysis |
| US6875893B2 (en) * | 2002-05-23 | 2005-04-05 | Cephalon, Inc. | Preparations of a sulfinyl acetamide |
| US7229644B2 (en) | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| WO2004012857A1 (en) | 2002-08-02 | 2004-02-12 | Avantium International B.V. | An assembly and method for performing parallel chemical experiments, in particular crystallisation experiments |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| DE60329415D1 (de) | 2002-12-06 | 2009-11-05 | Purdue Research Foundation | Pyridine zur behandlung von verletztemsäugetiernervengewebe |
| FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| KR101184797B1 (ko) | 2003-09-04 | 2012-09-20 | 세파론, 인코포레이티드 | 모다피닐 조성물 |
| US7566805B2 (en) * | 2003-09-04 | 2009-07-28 | Cephalon, Inc. | Modafinil compositions |
| EP1718607A4 (en) | 2004-02-06 | 2008-05-28 | Cephalon Inc | COMPOSITIONS BASED ON MODAFINIL |
| US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
| EP2708531A1 (en) | 2004-10-13 | 2014-03-19 | Pharmacia & Upjohn Company LLC | Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
| WO2007013962A2 (en) * | 2005-07-21 | 2007-02-01 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| JP2009508880A (ja) * | 2006-02-21 | 2009-03-05 | テバ ファーマシューティカル インダストリーズ リミティド | アルモダフィニルの新規な結晶形とその調製方法 |
| EP1954652A2 (en) | 2006-03-01 | 2008-08-13 | Teva Pharmaceutical Industries Ltd | An improved process for the preparation of armodafinil |
| US20100234468A1 (en) | 2007-06-04 | 2010-09-16 | Abhay Gaitonde | Novel process |
| WO2009024863A2 (en) | 2007-06-26 | 2009-02-26 | Actavis Group Ptc Ehf | Process for the preparation of modafinil enantiomers |
| US7960586B2 (en) | 2007-08-16 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Purification of armodafinil |
| US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
| EP1911739A3 (en) * | 2007-11-05 | 2008-09-17 | Dipharma Francis S.r.l. | Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate |
| WO2009090663A1 (en) | 2008-01-15 | 2009-07-23 | Lupin Limited | Novel crystalline polymorph of armodafinil and an improved process for preparation thereof |
-
2002
- 2002-12-20 FR FR0216412A patent/FR2849029B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-18 CN CN2007100017638A patent/CN101012189B/zh not_active Expired - Fee Related
- 2003-12-18 ES ES03799631.1T patent/ES2627808T3/es not_active Expired - Lifetime
- 2003-12-18 CN CNB2003801098134A patent/CN100540533C/zh not_active Expired - Fee Related
- 2003-12-18 MX MXPA05006525A patent/MXPA05006525A/es active IP Right Grant
- 2003-12-18 ES ES13177660.1T patent/ES2575018T3/es not_active Expired - Lifetime
- 2003-12-18 EP EP03799631.1A patent/EP1572635B1/fr not_active Expired - Lifetime
- 2003-12-18 EP EP13177658.5A patent/EP2679577A3/fr not_active Withdrawn
- 2003-12-18 SI SI200332281T patent/SI2343275T1/sl unknown
- 2003-12-18 PL PL377196A patent/PL377196A1/pl unknown
- 2003-12-18 NZ NZ571235A patent/NZ571235A/en not_active IP Right Cessation
- 2003-12-18 PT PT111636023T patent/PT2343275E/pt unknown
- 2003-12-18 BR BRPI0316916-2A patent/BRPI0316916B1/pt not_active IP Right Cessation
- 2003-12-18 KR KR1020057011619A patent/KR101050565B1/ko not_active Expired - Lifetime
- 2003-12-18 NZ NZ540733A patent/NZ540733A/en not_active IP Right Cessation
- 2003-12-18 EP EP11163602.3A patent/EP2343275B1/fr not_active Expired - Lifetime
- 2003-12-18 CA CA2510096A patent/CA2510096C/fr not_active Expired - Lifetime
- 2003-12-18 CA CA2724305A patent/CA2724305A1/fr not_active Abandoned
- 2003-12-18 ES ES11163602T patent/ES2425023T3/es not_active Expired - Lifetime
- 2003-12-18 JP JP2004564285A patent/JP4719471B2/ja not_active Expired - Fee Related
- 2003-12-18 EP EP13177648.6A patent/EP2679576A3/fr not_active Withdrawn
- 2003-12-18 CN CN201610461501.9A patent/CN106065007A/zh active Pending
- 2003-12-18 AU AU2003299349A patent/AU2003299349C1/en active Active
- 2003-12-18 US US10/539,918 patent/US7132570B2/en not_active Expired - Fee Related
- 2003-12-18 EP EP13177660.1A patent/EP2679578B1/fr not_active Expired - Lifetime
- 2003-12-18 WO PCT/FR2003/003799 patent/WO2004060858A1/fr active Application Filing
- 2003-12-18 EP EP13177661.9A patent/EP2676952A3/fr not_active Withdrawn
- 2003-12-18 EA EA200501016A patent/EA009592B1/ru not_active IP Right Cessation
- 2003-12-18 CN CN200910152177A patent/CN101654423A/zh active Pending
- 2003-12-18 CN CN2010101503175A patent/CN101914044A/zh active Pending
- 2003-12-18 DK DK11163602.3T patent/DK2343275T3/da active
- 2003-12-18 UA UAA200507106A patent/UA100964C2/ru unknown
- 2003-12-19 AR ARP030104730A patent/AR042546A1/es not_active Application Discontinuation
- 2003-12-22 TW TW092136443A patent/TWI344952B/zh not_active IP Right Cessation
- 2003-12-22 MY MYPI20034935A patent/MY142926A/en unknown
-
2005
- 2005-06-13 ZA ZA200504805A patent/ZA200504805B/en unknown
- 2005-06-15 NO NO20052912A patent/NO335724B1/no not_active IP Right Cessation
- 2005-06-16 IL IL169205A patent/IL169205A/en active IP Right Grant
- 2005-06-19 EG EGNA2005000326 patent/EG24849A/xx active
- 2005-07-19 IS IS7947A patent/IS7947A/is unknown
-
2006
- 2006-06-26 US US11/474,859 patent/US20060241320A1/en not_active Abandoned
-
2007
- 2007-08-22 CL CL2007002450A patent/CL2007002450A1/es unknown
-
2009
- 2009-07-22 US US12/507,594 patent/US20090281192A1/en not_active Abandoned
- 2009-07-22 US US12/507,584 patent/US9382200B2/en not_active Expired - Fee Related
- 2009-07-22 US US12/507,631 patent/US20100048720A1/en not_active Abandoned
- 2009-07-22 US US12/507,623 patent/US20090281193A1/en not_active Abandoned
- 2009-07-22 US US12/507,610 patent/US20100048719A1/en not_active Abandoned
- 2009-07-22 US US12/507,602 patent/US20100048718A1/en not_active Abandoned
-
2010
- 2010-08-20 AU AU2010212462A patent/AU2010212462A1/en not_active Abandoned
-
2011
- 2011-02-17 JP JP2011032155A patent/JP5497680B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-08 US US13/858,483 patent/US8729305B2/en not_active Expired - Fee Related
- 2013-07-08 CY CY20131100573T patent/CY1114291T1/el unknown
- 2013-08-28 US US14/012,363 patent/US8975442B2/en not_active Expired - Fee Related
-
2016
- 2016-10-17 CL CL2016002640A patent/CL2016002640A1/es unknown
- 2016-12-01 HK HK16113750.5A patent/HK1225371A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7947A (is) | Aðferð til að framleiða kristölluð form ljósfræðilegra handhverfa módafíníls | |
| DE60311599T2 (de) | Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten | |
| SE0103046D0 (sv) | Kristallin bas av citalopram | |
| PT100673B (pt) | Processo para a preparacao de intermediarios de sertralina e compostos assim obtidos | |
| NO170685B (no) | Optisk aktive alkyl-aryl-ketaler | |
| ES2170732A1 (es) | Procedimiento para preparar citalopram purificado | |
| Kato et al. | Improved synthetic methods of CP-060S, a novel cardioprotective drug | |
| RS50673B (sr) | Postupak pripremanja racemskog citaloprama i/ili s- ili r-citaloprama separacijom smeše r- i s-citaloprama | |
| PT768309E (pt) | Processo para a preparacao de compostos de imidazolilo enantiomericamente puros | |
| KR102236806B1 (ko) | 거울상 이성질체 농후화된 3-아미노피페리딘의 제조 방법 | |
| BR0109507A (pt) | Processo para preparação de forma i, cristalina, de carbegolina | |
| PT759904E (pt) | Processo e sais diastereomericos uteis para a resolucao optica de alfa-¬4-(1,1-dimetiletil)-fenil|-4-(hidroxidifenilmetil)-1-piperidinobutanol racemico e compostos derivados | |
| ES2307209T3 (es) | Procedimiento de produccion de un enantiomero de amlodipina con una pureza optica alta. | |
| WO2001083422A1 (en) | Process for the separation of the cis trans diastereoisomers of tramadol | |
| BR102013004752A2 (pt) | Processo para a transformação de medetomidina e recuperação do enantiômero indesejado | |
| Asberom et al. | Tetrahydroquinoline sulfonamides as γ-secretase inhibitors | |
| ES2323742T3 (es) | Derivados de 4-(aril)(ariloxi)metil piperidina y su uso como inhibidores de la recaptacion de serotonina y/o noradrenalina. | |
| AR030938A1 (es) | Proceso de obtencion de los enantiomeros de la cetamina racemica; proceso de obtencion de sales farmaceuticamente aceptables de enantiomeros de la cetamina racemica y utilizacion de las sales farmaceuticamente aceptables obtenidas por el referido proceso | |
| AR037005A1 (es) | Derivados de acidos dimetilfenilaceticos, derivados de piperidina, y proceso para la produccion de derivados de piperidina. | |
| EA200201236A1 (ru) | Новый полиморф v торасемида | |
| WO2004108665A2 (en) | A process for preparation of clopidogrel | |
| ATE402157T1 (de) | Verfahren zur herstellung von mycophenolatmofetil | |
| ES2214263T3 (es) | 3-bicicloaril-2-aminometil bicicloalcanos como inhibidores de la recaptacion de serotonina. | |
| AR012346A1 (es) | Proceso para la fabricacion de compuestos racemicos, compuestos obtenidos por dicho proceso y compuestos intermediarios | |
| KR101842425B1 (ko) | 시탈로프람 및 에스시탈로프람의 신규 제조방법 |